This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Energous (WATT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Energous (WATT) delivered earnings and revenue surprises of 12.50% and 22.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ADT (ADT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ADT (ADT) delivered earnings and revenue surprises of 20% and 3.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of 6.67% and 32.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for February 15th
by Zacks Equity Research
ATGE, ALGN, and APDN have been added to the Zacks Rank #5 (Strong Sell) List on February 15, 2022
Applied DNA Sciences (APDN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -231.58% and 2.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Napco (NSSC) Lags Q2 Earnings Estimates
by Zacks Equity Research
Napco (NSSC) delivered earnings and revenue surprises of -66.67% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Applied DNA Sciences (APDN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Applied DNA Sciences (APDN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson Controls (JCI) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson Controls (JCI) delivered earnings and revenue surprises of 1.89% and 1.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -53.13% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Applied DNA Sciences (APDN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -91.67% and -50.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Applied DNA Sciences (APDN) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for June 29th
by Zacks Equity Research
ITRG, TARA, QTNT, VNCE and APDN have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2021.
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Applied DNA Sciences (APDN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Applied DNA Sciences (APDN)
by Zacks Equity Research
Applied DNA Sciences (APDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Applied DNA Sciences (APDN) Moves 13.2% Higher: Will This Strength Last?
by Zacks Equity Research
Applied DNA Sciences (APDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Applied DNA Sciences (APDN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Applied DNA Sciences (APDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -12.73% and 15.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Applied DNA Sciences (APDN) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for January 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Applied DNA Sciences (APDN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -38.98% and -55.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Corporate News for May 15, 2020
by Zacks Equity Research
Companies In The News Are: APDN, CSCO, IMUX, VRTU